title: Effects of alpha lipoic acid supplementation on serum levels of IL-8 and TNF-α in patient with ESRD undergoing hemodialysis.
abstract: BACKGROUND
  Chronic renal failure is a progressive and irreversible loss of kidney function, and the hemodialysis (HD) is one of the most common modalities in this regard. Oxidative stresses [like interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α)] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients; meanwhile, antioxidants like alpha lipoic acid (ALA) may reduce the oxidative stress markers and the levels of inflammatory cytokines, so can improve of the patient's quality of life.
  
  
  METHODS
  In this randomized clinical trial study, 60 HD patients were randomly categorized in two case and control groups. Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks, and the control group received placebo capsules daily. The serum level of IL-8 and TNF-α was measured in both groups before and after the intervention.
  
  
  RESULTS
  There were no significant differences in age, gender, duration of dialysis, and causative factor for dialysis between both groups (P > 0.05). The mean of IL-8 and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61, respectively; the difference between both groups was not statistically significant (P > 0.05).
  
  
  CONCLUSIONS
  Based on the better feeling and other beneficial effects of ALA were found in our study; we can conclude that it is a beneficial and recommended supplement, especially, for diabetic and dialysis patients.
authors.affiliation: Chronic Kidney Diseases Research Center, Tabriz University of Medical Science, Tabriz, Iran, Drsafa2003@yahoo.com.
authors.forename: Javid
authors.initials: J
authors.lastname: Safa
authors.forename: Mohammad Reza
authors.initials: MR
authors.lastname: Ardalan
authors.forename: Mohammadamin
authors.initials: M
authors.lastname: Rezazadehsaatlou
authors.forename: Mehran
authors.initials: M
authors.lastname: Mesgari
authors.forename: Reza
authors.initials: R
authors.lastname: Mahdavi
authors.forename: Maryam Poorkar
authors.initials: MP
authors.lastname: Jadid
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000097:blood / Q000150:complications; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000209:etiology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D008063:Thioctic Acid / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood*
chemical_list: D000975:Antioxidants; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D008063:Thioctic Acid
references.citation: Free Radic Biol Med. 2000 Dec;29(11):1122-8
references.pmid: 11121719
references.citation: Am J Kidney Dis. 2003 Dec;42(6):1212-20
references.pmid: 14655193
references.citation: Semin Dial. 2002 Sep-Oct;15(5):329-37
references.pmid: 12358637
references.citation: Nephron Clin Pract. 2006;102(2):c51-8
references.pmid: 16224196
references.citation: Nephrol Dial Transplant. 2008 Mar;23(3):991-7
references.pmid: 18045815
references.citation: Intern Med. 2007;46(13):945-51
references.pmid: 17603231
references.citation: Free Radic Biol Med. 1996;21(6):845-53
references.pmid: 8902530
references.citation: Semin Nucl Med. 2008 Jan;38(1):32-46
references.pmid: 18096462
references.citation: Diabetes Care. 1999 Aug;22(8):1296-301
references.pmid: 10480774
references.citation: Diabetes. 1999 Oct;48(10):2045-51
references.pmid: 10512372
references.citation: Pediatr Nephrol. 2005 Jun;20(6):725-31
references.pmid: 15809833
references.citation: Clin J Am Soc Nephrol. 2006 Mar;1(2):182-92
references.pmid: 17699207
references.citation: J Ren Nutr. 2011 May;21(3):211-8
references.pmid: 21185738
references.citation: J Nutr. 2003 Nov;133(11):3327-30
references.pmid: 14608040
references.citation: Diabetes Technol Ther. 2000 Autumn;2(3):401-13
references.pmid: 11467343
references.citation: Diabetes Care. 2003 Mar;26(3):770-6
references.pmid: 12610036
references.citation: Ann Acad Med Stetin. 2004;50(1):41-52
references.pmid: 16871743
references.citation: Diabetes. 2000 Jun;49(6):1006-15
references.pmid: 10866054
references.citation: Cardiovasc Res. 2009 Dec 1;84(3):353-60
references.pmid: 19617600
references.citation: Horm Metab Res. 2004 Oct;36(10):716-20
references.pmid: 15523598
references.citation: Mol Aspects Med. 1994;15(4):293-376
references.pmid: 7845187
references.citation: Diabetes Care. 1997 Mar;20(3):369-73
references.pmid: 9051389
references.citation: Iran J Kidney Dis. 2011 Jul;5(3):175-81
references.pmid: 21525577
references.citation: Eur J Clin Invest. 2001 May;31(5):417-24
references.pmid: 11380593
references.citation: J Ren Nutr. 2012 Mar;22(2):244-250
references.pmid: 21908204
references.citation: Diabetes. 2001 Jun;50(6):1464-71
references.pmid: 11375349
references.citation: Ann Cardiol Angeiol (Paris). 2008 Jun;57(3):161-5
references.pmid: 18571145
references.citation: Am J Nephrol. 2007;27(1):70-4
references.pmid: 17259696
references.citation: Int Urol Nephrol. 2014 Jan;46(1):57-62
references.pmid: 23749031